Header Logo

Debra L Richardson

TitleProf,Asoc
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentGynecologic Oncology
AddressSOCC 5050
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yonemori K, Boni V, Min KG, Meniawy TM, Lombard J, Kaufman PA, Richardson DL, Bender L, Okera M, Matsumoto K, Giridhar KV, Garc?a-S?enz JA, Prenen H, de Speville Uribe BD, Dizon DS, Garcia-Corbacho J, Van Nieuwenhuysen E, Li Y, Estrem ST, Nguyen B, Bacchion F, Ismail-Khan R, Jhaveri K, Banda K. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study. Gynecol Oncol. 2024 Oct 22; 191:172-181. PMID: 39442371.
      Citations:    
    2. Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. J Clin Oncol. 2024 Sep 04; JCO2301107. PMID: 39231383.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289. PMID: 38627035.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghani A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice. Clin Cancer Res. 2024 Jul 30. PMID: 39078736.
      Citations:    Fields:    Translation:Humans
    5. Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regin?cov? K, Richardson DL, Perri T, Oza AM, Miller DS, Al?a EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednar?kov? M, Chon HS, Mart?nez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fari?as-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211. PMID: 38834399.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024 Mar 05; 185:186-193. PMID: 38447347.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 Mar; 46(3):228-238. PMID: 38423866.
      Citations:    Fields:    Translation:Humans
    8. Vergote I, P?rez-Fidalgo JA, Hamilton EP, Valabrega G, Gorp TV, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Mart?nez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, H?gdall E, Fari?as-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V, ENGOT-EN5/GOG-3055/SIENDO Investigators. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023 Sep 05; JCO2202906. PMID: 37669480.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    9. Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463. PMID: 37666539.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    10. Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300235. PMID: 37797273.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. Richardson DL. The emerging use of antibody-drug conjugates in ovarian cancer. Clin Adv Hematol Oncol. 2023 05; 21(5):244-246. PMID: 37145494.
      Citations:    Fields:    Translation:Humans
    12. Richardson DL, Eskander RN, O'Malley DM. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review. JAMA Oncol. 2023 Apr 20. PMID: 37079311.
      Citations: 19     Fields:    Translation:Humans
    13. Richardson DL. Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology. Gynecol Oncol Rep. 2023 Apr; 46:101148. PMID: 37033209; PMCID: PMC10073635.
      Citations:    
    14. Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):6-14. PMID: 36484278.
      Citations: 1     Fields:    Translation:Humans
    15. Zhou X, Richardson DL, Dowlati A, Goel S, Sahebjam S, Strauss J, Chawla S, Wang D, Mould DR, Samnotra V, Faller DV, Venkatakrishnan K, Gupta N. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2023 03; 12(3):257-266. PMID: 36382849.
      Citations: 3     Fields:    Translation:Humans
    16. Banerjee S, Drapkin R, Richardson DL, Birrer M. Targeting NaPi2b in ovarian cancer. Cancer Treat Rev. 2022 Nov 14; 112:102489. PMID: 36446254.
      Citations: 9     Fields:    Translation:Humans
    17. Krause D, Richardson DL. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):1-5. PMID: 36239548.
      Citations: 1     Fields:    Translation:Humans
    18. Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 08; 166(2):219-229. PMID: 35690498.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    19. Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49. PMID: 35491267.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    20. Richardson DL. Should we or should we not? Secondary debulking in ovarian cancer. Lancet Oncol. 2021 04; 22(4):412-413. PMID: 33705694.
      Citations: 1     Fields:    Translation:Humans
    21. Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121. PMID: 33541735.
      Citations: 28     Fields:    Translation:Humans
    22. Gillen JM, Grimes SC, Essel KG, Duininck GE, Zhao D, Thompson JS, Richardson DL. Association of financial assistance programs and time to completion of therapy in women receiving chemoradiation for cervical cancer. Gynecol Oncol Rep. 2020 Nov; 34:100660. PMID: 33251312.
      Citations: 1     
    23. Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370. PMID: 32847980.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    24. Son J, Chambers LM, Carr C, Michener CM, Yao M, Beavis A, Yen TT, Stone RL, Wethington SL, Fader AN, Burkett WC, Richardson DL, Staley AS, Ahn S, Gehrig PA, Torres D, Dowdy SC, Sullivan MW, Modesitt SC, Watson C, Veade A, Ehrisman J, Havrilesky L, Secord AA, Loreen A, Griffin K, Jackson A, Viswanathan A, Ricci S. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747. PMID: 32771986.
      Citations: 5     Fields:    Translation:Humans
    25. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601. PMID: 32114513.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    26. Beavis AL, Yen TT, Stone RL, Wethington SL, Carr C, Son J, Chambers L, Michener CM, Ricci S, Burkett WC, Richardson DL, Staley AS, Ahn S, Gehrig PA, Torres D, Dowdy SC, Sullivan MW, Modesitt SC, Watson C, Veade A, Ehrisman J, Havrilesky L, Secord AA, Loreen A, Griffin K, Jackson A, Viswanathan AN, Jager LR, Fader AN. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020 03; 156(3):568-574. PMID: 31948730.
      Citations: 8     Fields:    Translation:Humans
    27. Albuquerque K, Tumati V, Lea J, Ahn C, Richardson D, Miller D, Timmerman R. A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):464-471. PMID: 31697990.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    28. Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449. PMID: 31478762.
      Citations: 7     Fields:    Translation:Humans
    29. Richardson DL. New and Novel Therapies for Gynecologic Cancers. Semin Oncol Nurs. 2019 Apr; 35(2):217-219. PMID: 30876683.
      Citations: 7     Fields:    Translation:Humans
    30. Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22. PMID: 30806847.
      Citations: 16     Fields:    Translation:HumansAnimals
    31. Manders DB, Sims TT, Bailey A, Hwang L, Richardson DL, Miller DS, Kehoe SM, Albuquerque KV, Lea JS. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol. 2018 12; 41(12):1225-1230. PMID: 29782361.
      Citations: 8     Fields:    Translation:Humans
    32. Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. Am J Clin Oncol. 2018 Nov; 41(11):1137-1141. PMID: 29521650.
      Citations: 3     Fields:    
    33. Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937. PMID: 28817390.
      Citations: 5     Fields:    Translation:Humans
    34. Richardson DL, Seward SM, Moore KN. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1057-1071. PMID: 30390760.
      Citations: 4     Fields:    Translation:Humans
    35. Richardson DL, Coleman RL, Sill MW. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299. PMID: 29978183.
      Citations: 2     Fields:    Translation:Humans
    36. Manders DB, Kehoe SM, Miller DS, Lea JS, Richardson DL. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801. PMID: 28225444.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    37. Manders DB, Morón A, McIntire D, Miller DS, Richardson DL, Kehoe SM, Albuquerque KV, Lea JS. Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2018 05; 41(5):447-451. PMID: 27258678.
      Citations: 4     Fields:    Translation:Humans
    38. Parsons LHP, Pedersen R, Richardson DL, Kho KA. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2018 Apr; 223:108-112. PMID: 29518640.
      Citations: 7     Fields:    Translation:Humans
    39. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202. PMID: 29242937.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    40. Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483. PMID: 28756871.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    41. Bedell S, Manders D, Miller D, Lea J, Kehoe S, Richardson D, Carlson M. Response to "Towards implementation of sexual healthcare". Gynecol Oncol Rep. 2017 May; 20:139. PMID: 29892679; PMCID: PMC5993518.
      Citations:    
    42. Bedell S, Manders D, Kehoe S, Lea J, Miller D, Richardson D, Carlson M. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecol Oncol. 2017 03; 144(3):586-591. PMID: 28081881.
      Citations: 7     Fields:    Translation:Humans
    43. Conrad LB, Conrad SA, Miller DS, Richardson DL, Kehoe S, Lea JS. Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138. PMID: 27132089.
      Citations:    Fields:    Translation:Humans
    44. Tumati V, Folkert MR, Lawson S, Wise E, Wolcott S, Richardson D, Carlson M, Kehoe S, Lea J, Abdulrahman R, Albuquerque K. Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. Brachytherapy. 2016 May-Jun; 15(3):341-346. PMID: 27004686.
      Citations: 1     Fields:    Translation:Humans
    45. Kho KA, Lin K, Hechanova M, Richardson DL. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016 Mar; 127(3):468-473. PMID: 26855091.
      Citations: 13     Fields:    Translation:Humans
    46. Powell CB, Richardson DL, Chen LM. In response to Peshkin et al. "Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key". Gynecol Oncol Rep. 2015 Nov; 14:46. PMID: 26793775.
      Citations:    
    47. Lin KY, Miller DS, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, Lea JS. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5. PMID: 26186908.
      Citations: 10     Fields:    Translation:Humans
    48. Davidson BA, Nagel CI, Richardson DL, Kehoe SM, Miller DS, Lea JS. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. J Reprod Med. 2015 May-Jun; 60(5-6):243-8. PMID: 26126310.
      Citations: 1     Fields:    Translation:Humans
    49. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan; 136(1):3-7. PMID: 25238946.
      Citations: 106     Fields:    Translation:Humans
    50. Nagel CI, Thomas SK, Richardson DL, Kehoe SM, Miller DS, Lea JS. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5. PMID: 25014542.
      Citations: 1     Fields:    Translation:Humans
    51. Manders DB, Paulsen A, Richardson DL, Kehoe SM, Miller DS, Lea JS. Factors associated with clinical trial screening failures in gynecologic oncology. Gynecol Oncol. 2014 Sep; 134(3):450-4. PMID: 24992676.
      Citations: 4     Fields:    Translation:Humans
    52. Lin KY, Bryant S, Miller DS, Kehoe SM, Richardson DL, Lea JS. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9. PMID: 24836278.
      Citations: 13     Fields:    Translation:Humans
    53. Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DM. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8. PMID: 23640292.
      Citations: 5     Fields:    Translation:Humans
    54. Boren T, Lea J, Kehoe S, Miller DS, Richardson D. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012 Oct; 127(1):43-6. PMID: 22713294.
      Citations: 5     Fields:    Translation:Humans
    55. Seamon LG, Richardson DL, Copeland LJ. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar; 55(1):131-55. PMID: 22343234.
      Citations: 2     Fields:    Translation:Humans
    56. Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson DL. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar; 124(3):508-11. PMID: 22108254.
      Citations: 1     Fields:    Translation:Humans
    57. O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72. PMID: 21315428.
      Citations: 20     Fields:    Translation:Humans
    58. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31. PMID: 21495213.
      Citations:    Fields:    Translation:Humans
    59. Kothari R, Morrison C, Richardson D, Seward S, O'Malley D, Copeland L, Fowler J, Cohn DE. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010 Aug 01; 118(2):172-5. PMID: 20605625.
      Citations: 5     Fields:    Translation:Humans
    60. Seamon LG, Cohn DE, Richardson DL, Hurt JD, Nickerson EC, Fowler JM. Robotic pelvic and aortic lymphadenectomy for endometrial cancer: the console surgeon's perspectives on surgical technique and directing the assistant. J Minim Invasive Gynecol. 2010 Mar-Apr; 17(2):180-5. PMID: 20226405.
      Citations: 2     Fields:    Translation:Humans
    61. Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8. PMID: 19823054.
      Citations: 1     Fields:    Translation:Humans
    62. Seward SM, Richardson DL, Leon ME, Zhao W, Cohn DE, Hitchcock CL. Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotyping. Int J Gynecol Pathol. 2009 Sep; 28(5):497-501. PMID: 19696623.
      Citations: 2     Fields:    Translation:Humans
    63. Richardson DL, Seamon LG, Resnick KE, Martin D, Fowler JM. Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. Gynecol Oncol. 2009 Nov; 115(2):306-7. PMID: 19576621.
      Citations: 2     Fields:    Translation:Humans
    64. Seamon LG, Fowler JM, Richardson DL, Carlson MJ, Valmadre S, Phillips GS, Cohn DE. A detailed analysis of the learning curve: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Gynecol Oncol. 2009 Aug; 114(2):162-7. PMID: 19428096.
      Citations: 33     Fields:    Translation:Humans
    65. Seamon LG, Holt CN, Suarez A, Richardson DL, Carlson MJ, O'Malley DM. Paratubal borderline serous tumors. Gynecol Oncol. 2009 Apr; 113(1):83-5. PMID: 19189870.
      Citations: 6     Fields:    Translation:Humans
    66. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17. PMID: 19104354.
      Citations: 20     Fields:    Translation:Humans
    67. Seamon LG, Cohn DE, Richardson DL, Valmadre S, Carlson MJ, Phillips GS, Fowler JM. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008 Dec; 112(6):1207-1213. PMID: 19037027.
      Citations: 28     Fields:    Translation:Humans
    68. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9. PMID: 18954897.
      Citations: 278     Fields:    Translation:Humans
    69. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6. PMID: 18829088.
      Citations: 19     Fields:    Translation:Humans
    70. Richardson DL, Seamon LG, Carlson MJ, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6. PMID: 18768214.
      Citations: 6     Fields:    Translation:Humans
    71. Seamon LG, Cohn DE, Valmadre S, Richardson DL, Jayjohn LA, Jenson C, Lee K, Travis J, Nickerson E, Fowler JM. Robotic hysterectomy and lymphadenectomy for endometrial cancer: technical aspects and details of success-the Ohio State University method. J Robot Surg. 2008 Jul; 2(2):71-6. PMID: 27637503.
      Citations:    Fields:    
    72. Seamon LG, Richardson DL, Pierce M, O'Malley DM, Griffin S, Cohn DE. Local correction of extreme stomal prolapse following transverse loop colostomy. Gynecol Oncol. 2008 Dec; 111(3):549-51. PMID: 18304621.
      Citations: 5     Fields:    Translation:Humans
    73. Richardson DL, Seamon LG, Gong MC, Chapman DM, Cohn DE. Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51. PMID: 18042491.
      Citations:    Fields:    Translation:Humans
    74. Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):667-72. PMID: 16797684.
      Citations: 31     Fields:    Translation:Humans
    Richardson's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (226)
    Explore
    _
    Co-Authors (9)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _